Ibogaine vs. Suboxone and methadone: how do the approaches differ?

Methadone and buprenorphine, the main drug in Suboxone, are daily opioid medicines. People stay on them long term. In trials, they keep people in treatment and cut illicit opioid use [1][2]. Far fewer people die while on them [3][4]. Ibogaine is a short treatment, given under medical care. In three studies, withdrawal eased within days [5][6][7].

How do maintenance medication and ibogaine differ?

Maintenance medication and ibogaine take two different routes. Methadone and buprenorphine swap the opioid a person depends on for a steady daily dose of a prescribed one [1][2]. Ibogaine works as a detox. People take it once, or over a few days, as they stop opioids [5][7].

The evidence differs too. Maintenance medication rests on randomized trials and on large studies of death rates [1][2][3][4]. Most human data on ibogaine come from studies that follow treated people, with no comparison group [8][9].

People weighing the two usually want to know what each one offers. They also want to know whether the two can fit together. The wider picture on ibogaine is in the evidence overview for 2026.

In the ibogaine studies, people had health checks before the dose and medical care during it [5][7]. In maintenance trials, doctors often set the dose to suit each person [2].

How do methadone, buprenorphine and ibogaine work?

Methadone and buprenorphine are opioids themselves. They act on the same opioid receptors as heroin, which keeps withdrawal away [2]. Methadone is a full agonist, meaning it switches those receptors fully on [2]. Buprenorphine is a partial agonist, with a weaker effect at the same sites [2].

A dimmer switch is a useful picture. Methadone can turn the light all the way up. Buprenorphine turns it only part of the way. That partial action appears to make buprenorphine safer in overdose [2].

Timing matters as well. Methadone works for about a day, so one dose a day is enough [1]. People who use heroin often take it three or four times a day, since its action is shorter [1].

Ibogaine works on a different plan. It binds to many brain targets at once, including opioid receptors and the pumps that recycle serotonin and dopamine [8]. A 2019 research paper describes the way ibogaine reduces drug-seeking as unresolved [8].

The body turns ibogaine into a second compound, noribogaine [12]. In lab tests on rat brain tissue, both blocked the mu-opioid receptor [18]. Most ibogaine leaves the blood within a day [5]. In opioid-dependent patients given noribogaine directly, its half-life was 24 to 30 hours [19]. Half-life is the time the body takes to clear half of a dose. A separate article covers the pharmacology of ibogaine.

What does the research show for each approach?

Maintenance medication has a deep base of controlled evidence. In randomized trials, methadone kept people in treatment and cut heroin use better than approaches without opioid replacement [1]. Buprenorphine kept people in treatment better than placebo at every dose tested [2]. At high doses, it also reduced illicit opioid use in urine tests [2].

Compared directly, the two medicines differ mainly in retention. With doses adjusted to each person, methadone kept more people in treatment [2]. Among people who stayed, the two reduced opioid use equally [2].

Death rates are far lower during maintenance treatment. In a 2021 review of cohort studies, deaths from any cause ran at about half the rate seen outside treatment [4]. Deaths from suicide, drug-related causes and heart disease were all lower during treatment [4]. A 2017 review found people on methadone died at about a third of the rate they did out of treatment [3]. On buprenorphine, the rate was under half [3]. The lower death rate held across age, sex and region, and for people who inject drugs [4].

Ibogaine's human evidence is observational. In three studies, opioid withdrawal eased within about three days of treatment [5][6][7]. In Mexico, self-rated withdrawal fell from 31 points to 14 [6]. In New Zealand, it fell from about 25 to about 14, in a group mostly coming off methadone [7]. Higher scores mean worse withdrawal.

Changes in drug use followed. At one month, half the people treated in Mexico reported no opioid use in the past 30 days [6]. In New Zealand, scores on a standard drug-use measure fell by more than 80 percent over twelve months [7].

One person enrolled in the New Zealand study died during treatment [7]. The coroner judged the death very likely linked to ibogaine, most probably through a heart rhythm problem [7]. Reports link ibogaine to several deaths, mainly from cardiac events [11].

How does ibogaine fit with methadone or buprenorphine?

In two ibogaine studies, people switched off their usual opioid before the dose. In St Kitts and in a Dutch hospital study, they moved to short-acting morphine, then took ibogaine [5][11]. The Dutch patients were on methadone or buprenorphine. They had not managed to stop opioid use with standard care [11][20].

The two drugs share a pathway in the liver. Methadone inhibits CYP2D6, the enzyme that turns ibogaine into noribogaine [12]. A 2015 review judges methadone likely to slow ibogaine's breakdown as a result [12].

Think of CYP2D6 as a drain. On that picture, methadone would narrow the drain, so ibogaine would stay in the blood for longer. In a Dutch study, differences in CYP2D6 genes drove a more than tenfold spread in how fast patients cleared ibogaine [20]. In healthy volunteers, blocking the enzyme about doubled the total amount of ibogaine and noribogaine in the blood [21].

Methadone also lasts a long time in the body, so its withdrawal drags on [7]. Timing of the dose follows withdrawal. In St Kitts, staff scored withdrawal about 12 hours after the last morphine, just before the dose [5]. In New Zealand, the last opioid came 12 to 33 hours before treatment [7]. A separate article covers how ibogaine interrupts opioid withdrawal.

How long does each approach last, and when is risk highest?

Maintenance is meant to continue. Its lower death rates apply while a person stays in treatment [3].

Two windows carry extra risk. In the first four weeks of methadone, deaths ran at about double the rate for the rest of treatment [4]. Death rates held steady when people started buprenorphine [3].

The weeks after leaving maintenance carry the highest risk. In the first four weeks after stopping, deaths from any cause ran at six times the rate seen in ongoing treatment [4]. The rate stayed about double for the rest of the time out of treatment [4].

A similar pattern appears after detox. In a London study of inpatient opioid detox, the overdose deaths in the following months all came among people who had completed the program [16]. The authors link this to lost tolerance, which makes the effect of a return to heroin hard to predict [16]. The same concern applies after any detox, ibogaine included. A 2026 British prescribing guideline raises it for every drug treatment of opioid dependence [17].

Doctors also use methadone for short-term detox [22]. In randomized trials, methadone tapered over days or weeks reduced withdrawal severity [22]. Most patients in those trials later went back to heroin [22].

Ibogaine treatment is short by design. People take a single dose, or staggered doses over one to four days [5][7]. Noribogaine, its breakdown product, keeps circulating for days afterwards [5][19]. In healthy volunteers given noribogaine directly, its half-life ran 28 to 49 hours [23].

In St Kitts and New Zealand, the dose was one part of a longer process, with screening before it and supervision during it [5][7]. In New Zealand, most of the group reported stopping or cutting down their opioid use over the following year [7]. Three in four of those tested at twelve months had urine free of opioids [7].

Who each approach fits

The research describes who each approach has served. Maintenance is the option documented with lower death rates while people stay in treatment [3][4]. In England, the choice between methadone and buprenorphine is made case by case [10]. It weighs a person's history and their commitment to a long-term plan [10].

The ibogaine studies enrolled people who wanted to stop opioids. The Dutch patients had not managed to stop with standard care [11]. The UK trial took people seeking medically supervised withdrawal [24].

Heart screening decided who could take part. St Kitts excluded people with heart disease, a slow resting heart rate or long QT syndrome [5]. The Dutch study excluded people whose QT interval was already long or who took drugs that lengthen it [11]. People ruled out on those heart grounds are not candidates for ibogaine under these protocols [5][11].

What is each treatment like?

Maintenance is a daily routine. A missed dose of methadone brings on withdrawal [2]. In some places, daily clinic visits for methadone can make a job harder to keep [2]. In the few trials that compared side effects, the one difference found was more sleepiness on methadone [2].

Ibogaine is a short, intense stay that usually moves through two stages [5][25]. A vivid, dream-like stage comes first. It starts within a few hours of the dose and lasts about 4 to 8 hours [5][25]. A calm, thoughtful stage follows and lasts roughly 8 to 20 hours [25].

In the first stage, people see a stream of images. Many are memories of past events [25]. In St Kitts, people treated for opioid or cocaine dependence often said it felt like a waking dream [5]. Childhood memories came up for about four in ten [5].

The body feels it too. In a Dutch hospital study, every patient had a spell of severe, short-lived unsteadiness and could not walk without help [11]. Nausea and vomiting were common in St Kitts [5].

Sleep is often hard for up to three days, and sleep medicine helps [25]. Some people still felt mild effects a day after the dose, and these soon faded [5].

Heart checks run through the whole stay. In St Kitts, heart monitoring ran from an hour before the dose to a full day after it [5]. The Dutch team watched the heart for at least a day [11].

Looking back, most people in St Kitts said they felt a benefit [5]. Nine in ten said it helped with their drug problem [5]. A similar share said it gave them insight [5]. Half said they felt cleansed or reborn [5].

In New Zealand, even people who kept using some opioids spoke well of the experience [7]. A typical comment was that it gave them insight into their own situation [7].

Where the research goes next

Three directions are open. The first is controlled trials of ibogaine for opioid withdrawal.

The trial registry lists two randomized, blinded trials as completed, one in the UK and one in Spain [24][26]. The UK trial compares a single ibogaine dose with placebo [24]. The Spanish trial tests ibogaine as an aid to tapering off methadone [26]. Neither had posted results on the trial registry by October 2026 [24][26].

The second is a trial that places ibogaine and maintenance medication side by side in comparable patients. That design would show which people gain more from each route.

Heart monitoring for such trials already has a working model. The Dutch team checked the heart at set times for at least a day, and gave magnesium once the QT interval passed 500 milliseconds [11].

The third is longer follow-up after ibogaine. Maintenance research tracks deaths over years, across hundreds of thousands of people [3][4]. The ibogaine studies followed people for one to twelve months, and lost touch with some people along the way [5][6][7]. Tracking overdose and deaths in the year after treatment would let researchers weigh the two approaches on the same outcome. The open questions are set out in full in Open Questions: What Rigorous Ibogaine Trials Must Answer.

Frequently asked questions

Does ibogaine work for methadone withdrawal?

In a small New Zealand study, self-rated withdrawal fell within 12 to 24 hours of treatment [7]. Most people in it were coming off methadone [7]. In a Dutch hospital study of people on methadone or buprenorphine, most did not return to morphine in the day after a dose [11].

Can someone take ibogaine while on Suboxone?

In the studies, people on buprenorphine or methadone first switched to morphine, a short-acting opioid [11][20]. In St Kitts, the dose came once withdrawal had begun [5]. Both steps took place under medical supervision [5][11].

Which works better, methadone or Suboxone?

Methadone kept more people in treatment when doctors adjusted doses to each person [2]. Among those who stayed, methadone and buprenorphine, the main drug in Suboxone, cut opioid use equally [2]. Death rates held steady when people started buprenorphine, and ran higher in the first month of methadone than later on [3][4].

Does ibogaine treatment work?

In three studies of opioid dependence, withdrawal eased within about three days of treatment [5][6][7]. In New Zealand, most of the group reported stopping or cutting down opioid use over the next year [7]. One person enrolled in that study died during treatment [7].

Is ibogaine dangerous?

Ibogaine prolongs the heart's QT interval, which has been linked to sudden deaths [8]. In one hospital study, half the patients passed a QT of 500 milliseconds after a single dose [11]. Case reports describe heart problems several days, and sometimes weeks, after a dose [12].